Investigational drug · Phase 2
CAL101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
73
Any phase or sponsor naming "CAL101"
First trial start
2025
Jun 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAL101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CAL101" as an intervention, largest first.
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01732926 · 475 participants · Start Jan 2, 2013 · Primary completion May 17, 2016
Drug: Idelalisib; Rituximab and 2 more · For: Indolent Non-Hodgkin's Lymphomas
Sites: Huntsville, Alabama; Chandler, Arizona; Bakersfield, California · 144 sites in all
- Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )Pivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01569295 · 416 participants · Start Jun 15, 2012 · Primary completion Jun 10, 2019
Drug: Idelalisib; Rituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Huntsville, Alabama; Los Angeles, California; Palo Alto, California · 106 sites in all
- Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01980888 · 311 participants · Start Feb 5, 2014 · Primary completion May 30, 2016
Drug: Idelalisib; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Fullerton, California; La Jolla, California; Santa Maria, California · 91 sites in all
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLPivotal-lookingActive, not recruiting
Acerta Pharma BVAstraZeneca (AZN)
NCT02970318 · 310 participants · Start Feb 2, 2017 · Primary completion Sep 3, 2021
Drug: Acalabrutinib (ACP-196); Rituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Chandler, Arizona; Oxnard, California; Athens, Georgia · 157 sites in all
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01732913 · 295 participants · Start Jan 16, 2013 · Primary completion May 18, 2016
Drug: Placebo; Rituximab and 1 more · For: Indolent Non-Hodgkin's Lymphomas
Sites: Huntsville, Alabama; Chandler, Arizona; Duarte, California · 103 sites in all
- Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
Gilead SciencesGilead Sciences (GILD)
NCT01659021 · 261 participants · Start Dec 4, 2012 · Primary completion Aug 15, 2018
Drug: Idelalisib; Ofatumumab · For: Chronic Lymphocytic Leukemia
Sites: Duarte, California; Fresno, California; San Diego, California · 80 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT03568929 · 257 participants · Start May 25, 2018 · Primary completion Oct 29, 2021
Drug: Idelalisib · For: Follicular Non-Hodgkin's Lymphoma Refractory
Sites: Antwerp, Belgium; Amiens, France; Bourg-en-Bresse, France · 88 sites in all
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06846671 · 250 participants (planned) · Start Apr 10, 2025 · Primary completion May 15, 2028
Drug: Tacabrutideg; Bendamustine and 3 more · For: CLL; Chronic Lymphocytic Leukemia; SLL
Sites: Jonesboro, Arkansas; Los Angeles, California; San Diego, California · 134 sites in all
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07139873 · 250 participants (planned) · Start Sep 8, 2025 · Primary completion Jan 2029
Drug: DZD8586; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Nanjing, China; Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.
Hallén J, Vetrhus S, Sørgaard M, et al. · Br J Clin Pharmacol 2026
- Inhibition of PI3K rebalanced Th1/Th17/Treg and restored macrophage function in imiquimod-induced psoriasis.
Ma D, Zhang X, Mu J, et al. · Mol Immunol 2026
- PI3Kδ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy.
Turnquist A, Javaid A, Wilkins OM, et al. · J Immunol 2026
- Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.
Borchert SV, Hallén J, Hussain RI, et al. · J Pharmacol Exp Ther 2025
- PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
Kong C, Wu M, Lu Q, et al. · Leuk Res 2024
- A Novel Role for the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation.
Martucci NJ, Stoops J, Bowen W, et al. · Am J Pathol 2024
Also in development for Idiopathic Pulmonary Fibrosis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- BMS-986278AdmilparantPhase 33 trials
Bristol Myers Squibb · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- BI 1015550Phase 32 trials
Boehringer Ingelheim · Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- REGEND001Phase 32 trials
Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.